Three developments this week extended the sector's frontiers in different directions simultaneously — and none of them repeated each other.

On March 25, Neuron published 'The Neuroscience of Advanced Meditation' by Sacchet and Lieberman — the first peer-reviewed review in a tier-1 journal to treat advanced contemplative states (jhana, samadhi, cessation) as a distinct neuroscientific research program rather than folding them into the general mindfulness literature. That distinction matters: it is the difference between studying beginning runners and studying elite athletes. The paper establishes, at the level of a Cell Press flagship journal, that advanced meditation produces phenomena worth investigating on their own terms.

On March 26, Mississippi Governor Reeves signed HB314, creating a state-funded ibogaine clinical trial program — the first state to do so through a standalone signed law. Texas has a large funded initiative; Mississippi's law is structurally different because it was the first to cross the finish line via formal legislative action and gubernatorial signature for ibogaine specifically.

On March 28, CNN published a feature on legal psilocybin retreats across the U.S., anchored by the number 5,935 — clients served through Oregon's licensed service center program since its launch. Mainstream media coverage at that level of specificity signals the program has moved from curiosity to documented consumer reality.

Also this week: Compass Pathways confirmed its NDA submission for COMP360 (psilocybin) is on track for Q4 2026, with cash runway to 2028; Jhourney's co-founder articulated an AI-guided jhana curriculum vision on a high-profile podcast; and Nature Communications published a tFUS study in Parkinson's patients that extends the utility of transcranial focused ultrasound well beyond its prior meditation-adjacent applications.